Sugi Predict

Sugi Predict / Compounds / SCHEMBL435844

SCHEMBL435844

SCHEMBL435844

CC(=O)OC1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.50
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HPGD P15428 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ PDE4B Q07343 1/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13219346 0.86 HPGD (0.51) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL65675 0.86 HPGD (0.51) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL17392565 0.86 HPGD (0.51) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL23107582 0.86 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL690145 0.85 NR1H2 (0.50) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL29244745 0.84 HPGD (0.52) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL4334069 0.84 HPGD (0.52) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL9885679 0.84 NR1H2 (0.53) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL30915352 0.84 NR1H2 (0.49) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL1024755 0.82 HPGD (0.54) USP2SMN1; SMN2HPGDRECQLEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852104-A Dihydro-quinoline-2-ketone compound and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-10-29 — — CN disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-20230192690-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES PFIZER (US) 2023-06-22 — — US disclosed
EP-3786165-A1 SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2021-03-03 — — EP disclosed
EP-2534154-B1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-08-05 — — EP disclosed
US-9839623-B2 Tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-12-12 — — US disclosed
US-9839623-B2 Tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-12-12 — — US disclosed
US-9839623-B2 Tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-12-12 — — US disclosed
US-20160354338-A1 TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-12-08 — — US disclosed
US-20160354338-A1 TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-12-08 — — US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 — — EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 — — WO disclosed
CN-101506194-A Novel pyridine analogs ASTRAZENECA AB (SE) 2009-08-12 — — CN disclosed
CN-101472917-A Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (CB1) receptor ligands ASTRAZENECA AB (SE) 2009-07-01 — — CN disclosed
CN-101454286-A Process for producing phenoxypyridine derivative EISAI R&D MAN CO LTD (JP) 2009-06-10 — — CN disclosed
CN-101263133-A New pyridine analogues ASTRAZENECA AB (SE) 2008-09-10 — — CN disclosed
CN-101137628-A Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators ASTRAZENECA AB (SE) 2008-03-05 — — CN disclosed
CN-1902168-A Novel 1, 3-disubstituted azetidine derivatives as 5-HT 2A receptor ligands MERCK SHARP & DOHME (GB) 2007-01-24 — — CN disclosed
EP-1685100-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS Merck Sharp & Dohme Limited (GB) 2006-08-02 — — EP disclosed
WO-2005047246-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NR1H2 3409/4885USP2 80/4885SMN1; SMN2 1058/4885
US-20160354338-A1 TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME CES2, DNPEP, METAP2 NR1H2 2128/4885USP2 552/4885SMN1; SMN2 3667/4885
US-20230192690-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES CHRM1, CHRM5, CHRM2 NR1H2 391/4885USP2 4745/4885SMN1; SMN2 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.